期刊文献+

血清降钙素原预测患者血流感染的临床价值

Clinical value of serum procalcitonin in predicting bloodstream infection in patients
原文传递
导出
摘要 目的:探讨不同血清降钙素原水平预测患者血流感染的临床价值。方法:选取2014年1月至2015年12月新疆生产建设兵团医院所有进行过血培养和PCT检测的住院患者为研究对象,采用梅里埃VIDAS荧光免疫法检测患者血清降钙素原(PCT),梅里埃血培养仪及细菌鉴定仪进行血培养及细菌鉴定,定量检测数据用中位数(四分位间距)描述。PCT医学决定水平:0.5 ng/ml、2 ng/ml和10 ng/ml。结果:纳入研究的血培养患者共595例,其中血培养阳性患者(阳性组)205例,血培养阴性患者(阴性组)390例。检出G+球菌78株,G-杆菌122株,真菌5株。阳性组患者年龄、体温、呼吸频率均高于阴性组患者(P<0.05),而性别和心率两组间无差异(P>0.05)。阳性组与阴性组患者的各项检测指标比较,PCT、白细胞总数(WBC)和中性粒细胞总数(Neu)有差异(P<0.05),而C反应蛋白(CRP)无差异(P>0.05)。经校正年龄后,多因素logistic回归显示PCT、WBC是血培养阳性的独立预测因子。PCT 2~10 ng/ml的患者发生血流感染的风险是PCT<0.5 ng/ml的2.789倍(95%CI:1.478,5.253);PCT≥10 ng/ml的患者发生血流感染的风险是PCT<0.5 ng/ml的5.283倍(95%CI:2.944,9.637);PCT≥10 ng/ml的患者发生血流感染的风险是PCT0.5~2 ng/ml的3.337倍(95%CI:1.648,6.933)。PCT、WBC的ROC曲线下面积分别为0.713(95%CI:0.669,0.756)和0.605(95%CI:0.556,0.653)。当PCT为1.250 ng/ml时ROC曲线下面积最大,血培养阳性的灵敏度和特异度分别为59.51%和72.05%。结论:血培养患者随着血清PCT水平升高发生血流感染的风险增加。
出处 《兵团医学》 2020年第3期1-4,共4页 Journal of BingTuan Medicine
  • 相关文献

参考文献5

二级参考文献147

  • 1Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
  • 2Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
  • 3Wiedermann FJ,Kaneider N,Egger P, et al. Migration of human monocytes in response to procalcitonin [J]. Crit Care Med, 2002 , 30(5): 1112-1117.
  • 4Hoffmann G, Totzke G, Seibel M, et al. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin [J]. Crit Care Med, 2001, 29 (1): 112-126.
  • 5Morgenthaler NG, Struck J, Chancerelle Y,et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection [J]. Horm Metab Res, 2003 , 35 ( 5): 290-295.
  • 6Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin- influence of temperature,storage,anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations [J]. EurJ Clin Chem Clin Biochem, 1997 , 35 ( 8): 597-601.
  • 7Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J]. Ann Emerg Med, 2008 , 52 (1): 48-58.
  • 8Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31 (2): 349-355.
  • 9Hirakata Y,Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2008 , 61 (2): 170-174.
  • 10Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department : an observational study[J]. Crit Care, 2(XM, 8 (1): R12-20.

共引文献711

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部